Figure 1.
Major Ischemic Events, Ischemic Stroke, Stroke, Major Hemorrhage, and Minor Hemorrhage in POINT by treatment group and by CYP2C19 metabolizer phenotype (as defined by the CHANCE trial)
Abbreviations: POINT, Platelet-oriented Inhibition in New TIA and minor ischemic stroke trial; CHANCE, Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events trial; CI, confidence interval; NE, not estimable